KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Cash from Financing Activities (2016 - 2025)

Inovio Pharmaceuticals' Cash from Financing Activities history spans 16 years, with the latest figure at $24.9 million for Q3 2025.

  • For Q3 2025, Cash from Financing Activities rose 3672.4% year-over-year to $24.9 million; the TTM value through Sep 2025 reached $55.1 million, up 127.82%, while the annual FY2024 figure was $51.5 million, 930.52% up from the prior year.
  • Cash from Financing Activities for Q3 2025 was $24.9 million at Inovio Pharmaceuticals, up from -$34777.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $160.9 million in Q1 2021 and bottomed at -$11.4 million in Q1 2024.
  • The 5-year median for Cash from Financing Activities is $3.4 million (2021), against an average of $19.8 million.
  • The largest annual shift saw Cash from Financing Activities tumbled 2575.77% in 2024 before it soared 3672.4% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at $47.6 million in 2021, then plummeted by 85.99% to $6.7 million in 2022, then tumbled by 72.43% to $1.8 million in 2023, then surged by 1485.47% to $29.1 million in 2024, then dropped by 14.49% to $24.9 million in 2025.
  • Per Business Quant, the three most recent readings for INO's Cash from Financing Activities are $24.9 million (Q3 2025), -$34777.0 (Q2 2025), and $1.0 million (Q1 2025).